101 related articles for article (PubMed ID: 12621451)
1. HIV-1 proprotein processing as a target for gene therapy.
Cordelier P; Zern MA; Strayer DS
Gene Ther; 2003 Mar; 10(6):467-77. PubMed ID: 12621451
[TBL] [Abstract][Full Text] [Related]
2. Conditional expression of alpha1-antitrypsin delivered by recombinant SV40 vectors protects lymphocytes against HIV.
Cordelier P; Strayer DS
Gene Ther; 2003 Dec; 10(26):2153-6. PubMed ID: 14625571
[TBL] [Abstract][Full Text] [Related]
3. Antioxidant enzyme gene delivery to protect from HIV-1 gp120-induced neuronal apoptosis.
Agrawal L; Louboutin JP; Reyes BA; Van Bockstaele EJ; Strayer DS
Gene Ther; 2006 Dec; 13(23):1645-56. PubMed ID: 16871233
[TBL] [Abstract][Full Text] [Related]
4. Using gene delivery to protect HIV-susceptible CNS cells: inhibiting HIV replication in microglia.
Cordelier P; Strayer DS
Virus Res; 2006 Jun; 118(1-2):87-97. PubMed ID: 16414141
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of HIV-1 by an anti-integrase single-chain variable fragment (SFv): delivery by SV40 provides durable protection against HIV-1 and does not require selection.
BouHamdan M; Duan LX; Pomerantz RJ; Strayer DS
Gene Ther; 1999 Apr; 6(4):660-6. PubMed ID: 10476226
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of HIV-1 replication in primary human T cells transduced with an intracellular anti-HIV-1 p17 antibody gene.
Tewari D; Notkins AL; Zhou P
J Gene Med; 2003 Mar; 5(3):182-9. PubMed ID: 12666184
[TBL] [Abstract][Full Text] [Related]
7. In vivo processing of Pr160gag-pol from human immunodeficiency virus type 1 (HIV) in acutely infected, cultured human T-lymphocytes.
Lindhofer H; von der Helm K; Nitschko H
Virology; 1995 Dec; 214(2):624-7. PubMed ID: 8553565
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of alpha1-antitrypsin inhibition of cellular serine proteases and HIV-1 protease that are essential for HIV-1 morphogenesis.
Cordelier P; Strayer DS
Biochim Biophys Acta; 2003 Jul; 1638(3):197-207. PubMed ID: 12878320
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of simian/human immunodeficiency virus replication in CD4+ T cells derived from lentiviral-transduced CD34+ hematopoietic cells.
Braun SE; Wong FE; Connole M; Qiu G; Lee L; Gillis J; Lu X; Humeau L; Slepushkin V; Binder GK; Dropulic B; Johnson RP
Mol Ther; 2005 Dec; 12(6):1157-67. PubMed ID: 16168713
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of HIV-1 replication by combined expression of gag dominant negative mutant and a human ribonuclease in a tightly controlled HIV-1 inducible vector.
Cara A; Rybak SM; Newton DL; Crowley R; Rottschafer SE; Reitz MS; Gusella GL
Gene Ther; 1998 Jan; 5(1):65-75. PubMed ID: 9536266
[TBL] [Abstract][Full Text] [Related]
11. Lentiviral transduction of human T-lymphocytes with a RANTES intrakine inhibits human immunodeficiency virus type 1 infection.
Schroers R; Davis CM; Wagner HJ; Chen SY
Gene Ther; 2002 Jul; 9(13):889-97. PubMed ID: 12080383
[TBL] [Abstract][Full Text] [Related]
12. Trans-activated interferon-alpha2 delivered to T cells by SV40 inhibits early stages in the HIV-1 replicative cycle.
Cordelier P; Calarota SA; Strayer DS
J Hematother Stem Cell Res; 2002 Oct; 11(5):817-28. PubMed ID: 12427288
[TBL] [Abstract][Full Text] [Related]
13. Development of targeted gene transfer into human primary T lymphocytes and macrophages using high-titer recombinant HIV vectors.
Miyake K; Miyake N; Shimada T
J Biotechnol; 2007 May; 129(3):532-8. PubMed ID: 17307270
[TBL] [Abstract][Full Text] [Related]
14. SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional,and pol III promoters.
Jayan GC; Cordelier P; Patel C; BouHamdan M; Johnson RP; Lisziewicz J; Pomerantz RJ; Strayer DS
Gene Ther; 2001 Jul; 8(13):1033-42. PubMed ID: 11438838
[TBL] [Abstract][Full Text] [Related]
15. Effective transduction and stable transgene expression in human blood cells by a third-generation lentiviral vector.
Bai Y; Soda Y; Izawa K; Tanabe T; Kang X; Tojo A; Hoshino H; Miyoshi H; Asano S; Tani K
Gene Ther; 2003 Aug; 10(17):1446-57. PubMed ID: 12900759
[TBL] [Abstract][Full Text] [Related]
16. Antisense RNA sequences targeting the 5' leader packaging signal region of human immunodeficiency virus type-1 inhibits viral replication at post-transcriptional stages of the life cycle.
Chadwick DR; Lever AM
Gene Ther; 2000 Aug; 7(16):1362-8. PubMed ID: 10981662
[TBL] [Abstract][Full Text] [Related]
17. Protecting neurons from HIV-1 gp120-induced oxidant stress using both localized intracerebral and generalized intraventricular administration of antioxidant enzymes delivered by SV40-derived vectors.
Louboutin JP; Agrawal L; Reyes BA; Van Bockstaele EJ; Strayer DS
Gene Ther; 2007 Dec; 14(23):1650-61. PubMed ID: 17914406
[TBL] [Abstract][Full Text] [Related]
18. Expression of mutant and wild-type gag proteins for gene therapy in HIV-1 infection.
Miele G; Lever AM
Gene Ther; 1996 Apr; 3(4):357-61. PubMed ID: 8732168
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense.
Mautino MR; Morgan RA
Gene Ther; 2002 Apr; 9(7):421-31. PubMed ID: 11938457
[TBL] [Abstract][Full Text] [Related]
20. Characterization of human immunodeficiency virus type 1 Pr160 gag-pol mutants with truncations downstream of the protease domain.
Liao WH; Wang CT
Virology; 2004 Nov; 329(1):180-8. PubMed ID: 15476885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
